Skip to main
TVRD
TVRD logo

TVRD Stock Forecast & Price Target

TVRD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tvardi Therapeutics Inc's clinical candidate TTI-101 has demonstrated statistically significant improvements in fibrotic mediators and meaningful enhancements in lung function through favorable pharmacokinetic and pharmacodynamic data. The ongoing Phase 2 REVERT-IPF trial is expected to benefit from the robust pre-clinical results, indicating a positive outlook for TTI-101 in treating idiopathic pulmonary fibrosis (IPF). Additionally, the company's second product candidate, TTI-109, offers a significant advantage with approximately 80% bioavailability, enhancing the therapeutic potential for targeting STAT3 compared to both TTI-101 and existing therapies.

Bears say

Tvardi Therapeutics Inc. faces a negative outlook primarily due to concerns regarding the efficacy of its lead product candidate, TTI-101, in treating idiopathic pulmonary fibrosis (IPF). Clinical observations suggest that while TTI-101 has shown some mechanistic activity by reducing phosphorylated STAT3 levels, there is uncertainty about its therapeutic benefit, as the natural decline in forced vital capacity (FVC) among placebo patients may confound the expected outcomes. Additionally, discrepancies in baseline pulmonary function results and the inconsistent response of patients to TTI-101 highlight potential challenges in validating its success in clinical trials, raising further doubts about its commercial viability.

TVRD has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cara Therapeutics Inc (TVRD) Forecast

Analysts have given TVRD a Buy based on their latest research and market trends.

According to 7 analysts, TVRD has a Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cara Therapeutics Inc (TVRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.